<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057551</url>
  </required_header>
  <id_info>
    <org_study_id>U01MH062475</org_study_id>
    <secondary_id>U01MH062475</secondary_id>
    <secondary_id>U01MH061504</secondary_id>
    <secondary_id>U01MH061562</secondary_id>
    <secondary_id>U01MH061587</secondary_id>
    <secondary_id>U01MH061590</secondary_id>
    <secondary_id>U01MH062465</secondary_id>
    <secondary_id>U01MH062491</secondary_id>
    <secondary_id>U01MH062546</secondary_id>
    <secondary_id>U01MH063481</secondary_id>
    <nct_id>NCT00057551</nct_id>
  </id_info>
  <brief_title>Research Evaluating the Value of Augmenting Medication With Psychotherapy</brief_title>
  <acronym>REVAMP</acronym>
  <official_title>CBASP Augmentation for Treatment of Chronic Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This 24-week study, with a 12-month follow up period, will compare the effectiveness of
      antidepressant medication alone to the combination of psychotherapy and antidepressant
      medication in patients with chronic depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic depression affects approximately 5% of adults in the United States and is associated
      with significant functional impairment and high health care utilization. The combination of
      drug treatment and psychotherapy may be most effective in treating depression. This study
      will determine the effects of adjunctive psychotherapy in depressed patients who have failed
      to respond or have responded only partially to an initial trial medication.

      Participants receive an initial trial of antidepressant medication for 8 to 12 weeks.
      Participants who continue to have depressive symptoms are randomly assigned to add Cognitive
      Behavioral Analysis System of Psychotherapy (CBASP) or supportive therapy to their medication
      regimens or to continue pharmacotherapy alone for an additional 12 weeks. Assessments are
      made at 6 and 12 months post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>12 weeks</time_frame>
    <description>Hamilton Depression Scale (HAM-D)&lt;8 and does not meet DSM-IV criteria for Major Depressive Disorder for 2 consecutive visits</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">491</enrollment>
  <condition>Depression</condition>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>CBASP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive Behavioral System of Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brief Supportive Psychotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Brief Supportive Psychotherapy plus medication (Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medication Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Could be switch to or addition of escitalopram, bupropion, venlafaxine or mirtazapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Supportive Psychotherapy</intervention_name>
    <description>brief supportive psychotherapy</description>
    <arm_group_label>Brief Supportive Psychotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>CBASP</intervention_name>
    <description>psychotherapy developed for chronic depression</description>
    <arm_group_label>CBASP</arm_group_label>
    <other_name>Cognitive Behavioral Analysis System of Psychotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medication Only</intervention_name>
    <description>antidepressant medication</description>
    <arm_group_label>Medication Only</arm_group_label>
    <other_name>one of five antidepressants</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Major depressive episode

          -  Depressive symptoms &gt; 2 years without remission

          -  Hamilton Depression Scale (HAM-D) score &gt; 20

          -  Fluent in English

        Exclusion Criteria

          -  Psychotic disorders, bipolar disorder, post traumatic stress disorder, obsessive
             compulsive disorder, or eating disorder

          -  Serious, unstable, or terminal medical condition

          -  Axis II diagnosis of antisocial, schizotypal, or severe borderline personality
             disorder

          -  Previous treatment with CBASP

          -  Previous ineffective treatment with 4 of the medication treatments used in the study

          -  Substance abuse

          -  Pregnancy

          -  Not willing to end other psychiatric treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H Kocsis</last_name>
    <role>Principal Investigator</role>
    <affiliation>weill cornell mc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medical College Payne Whitney Clinic</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY- Stony Brook</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown University</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000 May 18;342(20):1462-70. Erratum in: N Engl J Med 2001 Jul 19;345(3):232.</citation>
    <PMID>10816183</PMID>
  </reference>
  <reference>
    <citation>Keller MB, Kocsis JH, Thase ME, Gelenberg AJ, Rush AJ, Koran L, Schatzberg A, Russell J, Hirschfeld R, Klein D, McCullough JP, Fawcett JA, Kornstein S, LaVange L, Harrison W. Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998 Nov 18;280(19):1665-72.</citation>
    <PMID>9831997</PMID>
  </reference>
  <reference>
    <citation>J. P. McCullough, Jr. Treatment for Chronic Depression. Cognitive Behavioral Analysis System of Psychotherapy, New York: Guilford Press, 2000</citation>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2003</study_first_submitted>
  <study_first_submitted_qc>April 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2003</study_first_posted>
  <results_first_submitted>April 7, 2015</results_first_submitted>
  <results_first_submitted_qc>May 3, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2016</results_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CBASP</title>
          <description>Cognitive Behavioral Analysis System of Psychotherapy</description>
        </group>
        <group group_id="P2">
          <title>BriefSP</title>
          <description>Brief Supportive Psychotherapy</description>
        </group>
        <group group_id="P3">
          <title>Medication Only</title>
          <description>An algorithm including Sertraline, Escitalopram
Bupropion SR or XL
Venlafaxine XR
Mirtazapine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="200"/>
                <participants group_id="P2" count="195"/>
                <participants group_id="P3" count="96"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="168"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CBASP</title>
          <description>Cognitive Behavioral Analysis System of Psychotherapy</description>
        </group>
        <group group_id="B2">
          <title>Brief Supportive P</title>
          <description>Brief Supportive Psychotherapyherapy</description>
        </group>
        <group group_id="B3">
          <title>Medication Only</title>
          <description>Sertraline
Escitalopram
Bupropion SR or XL
Venlafaxine XR
Mirtazapine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="200"/>
            <count group_id="B2" value="195"/>
            <count group_id="B3" value="96"/>
            <count group_id="B4" value="491"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="13.4"/>
                    <measurement group_id="B2" value="46.4" spread="11.7"/>
                    <measurement group_id="B3" value="45.3" spread="11.9"/>
                    <measurement group_id="B4" value="45.9" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="272"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="195"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Depression Scale</title>
          <description>Scores range from 0-72 with higher scores indicating more severe depression</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.52" spread="8.26"/>
                    <measurement group_id="B2" value="19.44" spread="8.31"/>
                    <measurement group_id="B3" value="18.4" spread="8.8"/>
                    <measurement group_id="B4" value="19.48" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Remission</title>
        <description>Hamilton Depression Scale (HAM-D)&lt;8 and does not meet DSM-IV criteria for Major Depressive Disorder for 2 consecutive visits</description>
        <time_frame>12 weeks</time_frame>
        <population>Refers to # of subjects who completed 12 weeks of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>CBASP</title>
            <description>Cognitive Behavioral Analysis System of Psychotherapy</description>
          </group>
          <group group_id="O2">
            <title>Brief SP</title>
            <description>Supportive Therapy</description>
          </group>
          <group group_id="O3">
            <title>Medication Only</title>
            <description>Sertraline
Escitalopram
Bupropion SR or XL
Venlafaxine XR
Mirtazapine</description>
          </group>
        </group_list>
        <measure>
          <title>Remission</title>
          <description>Hamilton Depression Scale (HAM-D)&lt;8 and does not meet DSM-IV criteria for Major Depressive Disorder for 2 consecutive visits</description>
          <population>Refers to # of subjects who completed 12 weeks of treatment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
                <count group_id="O2" value="168"/>
                <count group_id="O3" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="31.0"/>
                    <measurement group_id="O3" value="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CBASP</title>
          <description>Cognitive Behavioral Analysis System of Psychotherapy</description>
        </group>
        <group group_id="E2">
          <title>BriefSP</title>
          <description>Supportive Therapy</description>
        </group>
        <group group_id="E3">
          <title>Medication</title>
          <description>Sertraline
Escitalopram
Bupropion SR or XL
Venlafaxine XR
Mirtazapine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>FISER</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>moderate burden</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="200"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="195"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="96"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James H. Kocsis, M.D.</name_or_title>
      <organization>Weill Cornell Medical College</organization>
      <phone>212-746-5913</phone>
      <email>jhk2002@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

